Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations.

Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multiple effects of SGLT2 inhibitors on patients across the spectrum of cardiovascular diseases.

Informations de copyright

© Touch Medical Media 2023.

Déclaration de conflit d'intérêts

Disclosures: Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, Ioannis Pantazopoulos, and Dimitrios G Chatzis have no financial or non-financial relationships or activities to declare in relation to this article.